Cormorant Asset Management

Location

Boston, United States

Total investments

202

Average round size

81M

Portfolio companies

153

Rounds per year

18.36

Lead investments

23

Follow on index

0.24

Exits

78

Areas of investment
BiotechnologyHealth CareHealth DiagnosticsGeneticsMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

The main department of described VC is located in the Boston. The fund was located in North America if to be more exact in United States.

Among the most popular fund investment industries, there are Medical, Life Science. Besides, a startup needs to be aged 6-10 years to get the investment from the fund. For fund there is a match between the country of its foundation and the country of its the most frequent investments - United States. The fund has no exact preference in some founders of portfolio startups. In case when startup counts 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Audentes Therapeutics, Innovent Biologics, ZAI Lab

The increased amount of exits for fund were in 2018. The top activity for fund was in 2018. Despite it in 2019 the fund had an activity. The common things for fund are deals in the range of 50 - 100 millions dollars. When the investment is from Cormorant Asset Management the average startup value is 500 millions - 1 billion dollars. Considering the real fund results, this VC is 2 percentage points less often commits exit comparing to other organizations. This Cormorant Asset Management works on 22 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in 13-24 investment rounds annually.

We also calculated 2 valuable employees in our database.

The standard case for the fund is to invest in rounds with 6-7 partakers. Despite the Cormorant Asset Management, startups are often financed by ARCH Venture Partners, Third Rock Ventures, New Enterprise Associates. The meaningful sponsors for the fund in investment in the same round are Foresite Capital, Wellington Management, EcoR1 Capital. In the next rounds fund is usually obtained by EcoR1 Capital, Visionnaire Ventures, Senvest Capital.

Show more

Investor highlights

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Analytics

Total investments
202
Lead investments
23
Exits
78
Rounds per year
18.36
Follow on index
0.24
Investments by industry
  • Biotechnology (156)
  • Health Care (119)
  • Medical (78)
  • Therapeutics (72)
  • Pharmaceutical (53)
  • Show 41 more
Investments by region
  • United States (173)
  • China (9)
  • Switzerland (5)
  • United Kingdom (2)
  • Bermuda (1)
  • Show 5 more
Peak activity year
2020
Number of Unicorns
8
Number of Decacorns
9
Number of Minotaurs
6

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
9
Avg. valuation at time of investment
215M
Group Appearance index
0.99
Avg. company exit year
7
Avg. multiplicator
6.15
Strategy success index
1.00

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Immuneering 05 Jan 2021 Biotechnology, Medical, Pharmaceutical Early Stage Venture 62M United States, Massachusetts, Cambridge
Neurogene 16 Dec 2020 Biotechnology Early Stage Venture 115M United States, New York, New York
How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.